Genmab A (GMAB) EBIT (QoQ) (2019 - 2026)
Powered by 
Analysis
Genmab A (GMAB) EBIT (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 108.33% |
| Sep 30, 2025 | 83.76% |
| Jun 30, 2025 | 191.49% |
| Sep 30, 2024 | 331.19% |
| Jun 30, 2024 | 32.35% |
| Mar 31, 2024 | 104.03% |
| Dec 31, 2023 | -267.68% |
| Sep 30, 2023 | 1,129.75% |
| Jun 30, 2023 | 182.62% |
| Dec 31, 2021 | -90.01% |
| Sep 30, 2021 | 852.36% |
| Jun 30, 2021 | -93.07% |
| Mar 31, 2021 | 158.03% |
| Dec 31, 2020 | 60,887,651.33% |
| Sep 30, 2020 | -100.00% |
| Jun 30, 2020 | 20.08% |
| Mar 31, 2020 | 100,854,600.85% |
| Dec 31, 2019 | -100.00% |
| Sep 30, 2019 | 2,316.64% |